IgA deficiency (IgAD) and common variable immunodeficiency (CVID) often co-occur in families, associating with chronic inflammatory diseases such as celiac disease (CD). ICOS (inducible co-stimulator) and CTLA4 (cytotoxic T-lymphocyteassociated protein-4) may be important in both disorders, as ICOS is necessary for Ig class-switching and CTLA4 negatively regulates T-cell activation. Linkage and association of CD with CTLA4-ICOS is well documented, we thus aimed to further pinpoint CD susceptibility by haplotype-tagging analysis. We genotyped 663 CD families from Finland and Hungary, 575 additional CD patients from Finland, Hungary and Italy; 275 Swedish and Finnish IgAD individuals and 87 CVID individuals for 14-18 genetic markers in CTLA4-ICOS. Association was found between CTLA4-ICOS and both IgAD (P ¼ 0.0015) and CVID (P ¼ 0.0064). We confirmed linkage of CTLA4-ICOS with CD (LOD 2.38, P ¼ 0.0005) and found association of CTLA4-ICOS with CD (P ¼ 0.0009). Meta-analysis of the IgAD, CVID and CD materials revealed intergenic association (P ¼ 0.0005). Disease-associated markers were associated with lower ICOS and higher CTLA4 expression, indicating that the risk haplotypes contain functional variants. In summary, we identified a novel shared risk locus for IgAD, CVID and CD, the first report of association between CTLA4-ICOS and IgAD. Association between CD and CTLA4-ICOS was also confirmed in a large European data set.
Introduction
IgA deficiency (IgAD) is the most common primary immunodeficiency in humans, affecting approximately 1 in 600 individuals in the Caucasian population. It is characterized by a lack of serum and secretory IgA due to an unknown defect in terminal lymphocyte differentiation. Most affected individuals are asymptomatic; however, individuals with IgAD have a higher risk of developing autoimmune diseases than the general population. This includes a 10-fold risk of celiac disease (CD) 1,2 as well as recurrent respiratory and gastrointestinal infections. 3 Common variable immunodeficiency (CVID) is a rare primary immunoglobulin deficiency resulting in recurrent infections and autoimmune complications. In addition to the lack of IgA, CVID patients have reduced serum levels of other immunoglobulin isotypes and patients often require immunoglobulin replacement therapy. IgAD and CVID can occur within the same families, with familial inheritance of either IgAD or CVID being reported in approximately 20% of cases. 4 The defects in antibody production are thought to represent a disease severity gradient from IgAD to CVID, with IgAD patients sometimes progressing to CVID over time. 5 IgAD is a genetic disorder, at least in part, but it does not follow a Mendelian inheritance pattern. Many multicase families show a dominant transmission of the disorder, whereas in other families, it follows autosomal recessive inheritance. 6, 7 No primary genetic factor has been identified and variation in familial inheritance patterns suggests that IgAD may be due to multiple genetic defects. Several studies have shown association of HLA alleles with IgAD, [8] [9] [10] [11] and the extended haplotype HLA-A1-B8-DR3 occurs more frequently in individuals with IgAD than it does in the general population. This haplotype is known as an autoimmunity risk haplotype as it is associated with several autoimmune pathologies. 12 However, the HLA haplotype does not explain all the genetic susceptibility to IgAD, and genes encoding molecules involved in B-cell differentiation or regulation of class-switching are potential non-HLA risk candidates.
Celiac disease is a chronic inflammatory disorder of the small intestinal mucosa that is induced by dietary gluten antigens in wheat, rye and barley. The only treatment of the disease is strict life-long exclusion of gluten. The prevalence of CD is approximately 1% in European populations and the disease is strongly associated with the HLA alleles DQB1*02 (serological DQ2) or DQB1*0302 (serological DQ8). These HLA alleles are necessary but not sufficient for the development of CD and non-HLA risk genes also contribute to disease susceptibility. Several studies have identified linkage or association of CD with the 2q33 locus, a region harboring the candidate genes CD28, CTLA4 and ICOS, three important regulators of T-cell activity. 13 Association between the CTLA4 region and CD has been demonstrated in several populations, in a number of studies. 14, 15 We have previously investigated this gene cluster in Finnish CD families and found linkage 16 as well as association with a haplotype within the ICOS gene. 17 ICOS (inducible co-stimulator) and CTLA4 (cytotoxic T-lymphocyte-associated protein-4) belong to the CD28 family of T-cell co-stimulatory receptors that are expressed on T cells following activation. ICOS plays a pivotal role in T helper cell-dependent B-cell responses, influencing isotype switching as well as inducing secretion of cytokines.
18 CTLA4 is a negative regulator of T-cell-mediated immunity and may be crucial for tolerance induction. 19 Apart from CD, the 2q33 locus has been studied as a candidate susceptibility locus for autoimmune diseases such as type I diabetes 20 and autoimmune thyroid disease. 21 In addition, a large deletion affecting exons 2 and 3 of the ICOS gene has been described in four CVID patients from two families. 22 This 1815 bp deletion results in an mRNA frameshift with a premature stop codon, abolishing the expression of ICOS at the cell surface. This finding was replicated in two further CVID families but this deletion is extremely rare, explaining CVID in less than 1% of patients and it is likely that all nine CVID patients share a common founder. 23 To date, common variants in the ICOS region have not been studied in CVID or other immunodeficiencies.
In this study, the association between Ig immunodeficiency and genetic variants within the CTLA4-ICOS region was investigated by studying polymorphisms in cohorts of IgAD and CVID patients. In addition, our earlier studies on the 2q33 gene region in CD were extended by using larger patient materials from three European populations and employing a systematic haplotype-tagging single nucleotide polymorphism (SNP) approach throughout the region.
Results
To identify whether CTLA4 and ICOS are involved in susceptibility to IgAD, 231 Swedish individuals with IgAD and 267 controls were genotyped for 18 SNPs within the CTLA4-ICOS region. IgAD was found to be associated with seven of the markers, with the CTLA4 marker rs2882974 demonstrating the highest significance (P ¼ 0.0015, odds ratio (OR) 1.50, 95% confidence interval (CI) 1.17-1.93) (Tables 1 and 5b) .
When all of the Swedish IgAD patients and controls were genotyped for the known autoimmunity risk haplotype HLA-DRB1*03-DQB1*02, the CTLA4 association was even stronger (P ¼ 0.0014, OR 2.10, 95% CI 1.33-3.32) in patients carrying the risk HLA haplotype (Tables  1 and 5B ). The G-C-G haplotype of rs231755-rs2882974-rs10497873 was significantly associated with protection from IgAD (P ¼ 0.005, OR 0.69, 95% CI 0.53-0.90), and the T-G haplotype of rs2882974-rs10497873 was signficantly associated with IgAD risk (P ¼ 0.0015, OR 1.50, 95% CI 1.17-1.93) as shown in Table 5B . Association was not detected in a small set of Finnish IgAD individuals (n ¼ 44, data not shown). Statistically significant association (P ¼ 0.0315, OR 1.63, 95% CI 1.04-2.55) was observed between the T allele of the CTLA4 marker rs16840252 and CVID (Tables 1 and 5b ). The T-C-A-G-T-G haplotype of rs16840252-rs5742909-rs231775-rs3087243-rs960792-rs231755 was significantly associated with risk of CVID (P ¼ 0.0064, OR 2.66, 95% CI 1.28-5.53; Table 5b ). Strong linkage disequilibrium (LD) was observed between the alleles of all CTLA4 markers and markers in the 5 0 region of ICOS (CTLA4-ICOSe1 LD block; Figure 1 ).
To confirm the association between CD and 2q33, CD case-control materials from the Italian, Finnish and Hungarian populations were genotyped for SNPs within CTLA4 and ICOS. Six markers in the CTLA4-ICOS region demonstrated association with CD in the Italian population (P ¼ 0.0009-0.0209; Tables 2 and 5b ). An association with the G-T-G haplotype of the markers rs231755, rs2882974 and rs10497873 was also observed (P ¼ 0.0006, OR 1.81, 95% CI 1.28-2.54; Table 5b ). In addition, the individual marker rs10932037 and the haplotype G-G-T of the adjacent markers ICOSivs4 þ 1070, rs10172036 and rs10932037 in the ICOS gene were associated with CD in the Finnish case-control material (P ¼ 0.0048, OR 1.98, 95% CI 1.22-3.19 and P ¼ 0.0009, OR 4.65, 95% CI 1.74-12.43, respectively). No association was found in the Hungarian CD case-control material (Table 2) .
Linkage between the CTLA4-ICOS gene region and CD was seen in Finnish families (LOD 2.21, P ¼ 0.0007) and the P-value was close to significant in Hungarian families (LOD 0.52, P ¼ 0.06). Combining the Finnish and Hungarian CD family material for analysis demonstrated the highest linkage (LOD 2.38, P ¼ 0.0005). Transmission disequilibrium test (TDT) analysis of 278 Finnish and 385 Hungarian families combined showed association of CD with rs10932029*T (P ¼ 0.048, OR 1.41, 95% CI 0.93-2.14; Tables 3 and 5b) , and also an ICOS haplotype of the markers rs3116505-rs11883722-rs10932029-rs4675374 (P ¼ 0.00067, OR 2.30, 95% CI 1.47-3.61; Table 5b ). Using the combined data sets, the TDT had 48% power to detect a risk allele, if the risk allele frequency is estimated to be 0.14 and relative risk is 1.28 as based on our previous analyses with rs10932029. 17 A Cochran-Mantel-Haenszel meta-analysis of the combined Finnish, Swedish, Hungarian and Italian case-control materials with CD, IgAD and CVID was performed, analyzing a total of 942 cases and 1126 controls (Tables 4 and 5b; Figure 2 ). Association of the intergenic markers rs2882974, rs11571311 and rs3116505 Abbreviations: CTLA4, cytotoxic T-lymphocyte-associated protein-4; CVID, common variable immunodeficiency; HLA, human leukocyte antigen; ICOS, inducible co-stimulator; IgAD, IgA deficiency. The frequency of the associated allele in cases and controls is shown, as well as its P-value (if P-value less than 0.05) and its odds ratio (OR) and 95% confidence interval (CI). Given that the associations found in CD differed among the three populations, putative risk and protective CD and IgAD haplotypes were compared with each other and to the results of previously reported genetic analyses in CD. This was performed by constructing haplotypes of the region from the combined genotype data of this study and public HapMap CEU data, including additional markers reported in other studies (Table 5a ).
CTLA4-ICOS locus in celiac disease and IgAD
The 20 haplotypes in the CTLA4-ICOSe1 block with over 0.5% prevalence were classified into five main groups (1a to 5d) based on their similarity, and 14 haplotypes (i-v) were observed in the ICOSe2-5 block (Table 5a ). The marker alleles and haplotypes associated with disease risk in the Italian population, the HLA-DR3-DQ2-positive Swedish IgAD patients and in the metaanalysis of all case-control materials, all belonged to CTLA4-ICOSe1 haplotype group 2. The protective associations in all these cohorts instead pointed to CTLA4-ICOSe1 haplotype group 1. For the Finnish-Hungarian CD family material, the HLA-DR3-DQ2-negative IgAD patients, and for IgAD patients in general, the markers and haplotypes associated with disease risk pointed to CTLA4-ICOSe1 haplotype group 4, which also seems to carry the previously reported Scandinavian and Dutch CD risk alleles and haplotypes. 24, 25 To investigate the role of polymorphisms in CTLA4-ICOS on gene expression, previously published 26 mRNA expression data of ICOS, full-length CTLA4 (flCTLA4) and soluble CTLA4 (sCTLA4) splice variants in CD4 þ T cells were re-analyzed based on the current expanded genotyping results (Table 5d ; Supplementary  Figure 1) . Earlier, rs3087243, rs10932029 and rs10932037 genotypes were demonstrated to affect the expression of CTLA4 and ICOS. 26 In the current study, three additional SNPs were found to influence gene expression (Table 5d ; Supplementary Figure  1 ). Rs11571300*A was associated with increased levels of both the flCTLA4 (P ¼ 0.009) and sCTLA4 (P ¼ 0.029) isoforms upon stimulation, as well as with a higher flCTLA/ICOS ratio in stimulated cells (P ¼ 0.004). In addition, rs231755*G was associated with higher sCTLA4 levels in stimulated cells (P ¼ 0.036) and a higher flCTLA4/ICOS ratio (P ¼ 0.036). In contrast, rs11571311*T correlated with lower ICOS expression levels in stimulated cells (P ¼ 0.046). A number of these alleles showed disease associations in the above-mentioned genetic tests (Table 5b) .
To determine whether HLA and CTLA4-ICOS risk haplotypes influence serum levels of IgA, we measured total IgA levels from 89 control subjects genotyped for the SNPs within the CTLA4-ICOS region and the HLA- Abbreviations: CTLA4, cytotoxic T-lymphocyte-associated protein-4; ICOS, inducible co-stimulator. The frequency of the associated allele in cases and controls is shown, as well as its P-value (if P-value less than 0.05) and odds ratio (OR) and 95% confidence interval (CI). CTLA4  rs16840252  CTLA4À1147  T  37  31  64  59  101  87  CTLA4  rs231775  CTLA4+49  A  60  66  93  92  153  158  CTLA4  rs3087243  CT60  A  53  66  70  85  123  151  CTLA4  rs11571300  A  31  22  43  37  74  59  Intergenic  rs960792  C  57  69  86  89  143  158  Intergenic  rs231755  C  36  26  67  60  103  86  Intergenic  rs2882974  T  66  60  105  89  171  149  Intergenic  rs11571311  T  34  48  67  63  101  111  Intergenic  rs3116505  C  70  69  91  86  161  155  ICOS  rs11883722  G  39  48  66  75  105  123  ICOS  rs10932029  ICOSivs+173  T  32  20  47  36 Abbreviations: CD, celiac disease; CTLA4, cytotoxic T-lymphocyte-associated protein-4; ICOS, inducible co-stimulator. The number of transmitted and untransmitted alleles is shown, as well as the associated P-value (if P-value less than 0.05) and odds ratio (OR) and 95% confidence interval (CI).
K Haimila et al DR3-DQ2 haplotype. No statistically significant differences were detected (data not shown).
Discussion
Genetic defects at the 2q33 locus appear to be involved in the development of several chronic inflammatory conditions, especially autoimmunity, but the precise causal genetic factor is yet to be identified. There have been numerous reports of linkage or association of the nearby CTLA4 and ICOS genes with several diseases, although most of the earlier studies have focused their analysis on only a few CTLA4 polymorphisms. There is a recombination hot spot in the first intron of ICOS, dividing the gene into two LD blocks, 27 referred to as CTLA4-ICOSe1 and ICOSe2-5 in Figure 1 . This strong LD makes it challenging to distinguish between association with CTLA4 and the promoter of ICOS.
Earlier studies on CD in the Finnish population revealed linkage to 2q33 16 and association with an ICOS haplotype but not with markers in CTLA4.
17, 28 The current study extended the Finnish family material and significant linkage remained. Interestingly, despite genotyping additional intergenic tagging SNPs, the strongest association in the Finnish CD material was still found with SNPs in the ICOSe2-5 haploblock. Hungarian CD families did not show statistically significant linkage, but the combined Finnish and Hungarian families revealed an association with intergenic markers in the CTLA4-ICOSe1 block. In contrast, the Italian case-control material showed association with several markers in the CTLA4 gene itself and throughout the CTLA4-ICOSe1 block, including the rs231775*A (CTLA4 þ 49*A) allele. This variant has previously been shown to be associated with CD in another Italian cohort 29 and in several other populations, 24, 25, [30] [31] [32] [33] as shown in Table 5c . To date, common variants in CTLA4-ICOS have not been analyzed in IgAD and CVID despite the involvement of ICOS in Ig class-switching, and this study is the first to report an association between the CTLA4-ICOS region and IgAD. In the Swedish case-control material, several SNPs in both haploblocks showed association with IgAD. Furthermore, HLA-stratified two-locus analysis provided evidence of epistasis between these two loci.
Although the mechanisms for this interaction remain unclear, epistasis between CTLA4 and HLA has been previously reported in type I diabetes 34, 35 and CD. 25, 29 A recent study by Butty et al. 27 of LD patterns and haplotypes in the CD28-CTLA4-ICOS gene region in a number of populations revealed extended haplotypes covering the whole region. Our finding of LD between markers in the CTLA4-ICOSe1 and ICOSe2-5 haploblocks supports this. The structure and frequency of haplotypes in the current study are also in accordance with those in the European populations studied by Butty et al. 27 The haplotype identified as most common in those European populations is part of our CTLA4-ICOSe1 risk haplotype group 2. Both our risk haplotype groups 2 and 4 carry the allele most commonly associated with CD, rs231775*A (CTLA4 þ 49*A) (Table 5a ). However, this allele is also carried in the protective haplotype group 3, indicating that it is not the primary functional disease variant. A risk haplotype for CD, C-G-G, was reported in the UK population. 36 This haplotype is frequent in protective CTLA4-ICOSe1 haplotype group 1, but also in haplotype group 5 which further shares risk alleles with haplotype group 4. The most common CTLA4-ICOSe1 haplotype in Europe, 1a, carries this smaller C-G-G haplotype, but is also in LD with ICOSe2-5 haplotype k carrying the alleles associated with CD risk in Finland. In a recent genome-wide association study in the UK population, the only CTLA4-ICOS variant showing association with CD was rs4675374*T, located in the first intron of ICOS. 37 This allele is carried in our risk CTLA4-ICOSe1 haplotype groups 2 and 4, although it is also present in some protective haplotypes. In addition, a study from Ireland reported the protective effect of a C-A-A haplotype in CD; 38 this smaller haplotype occurs frequently in our risk CTLA4-ICOSe1 haplotype group 2 but also exists in the protective haplotype groups 1 and 3. Hence, our results perhaps explain the apparently contradictory results in earlier studies (Table 5c ). Our results suggest that the true risk variants for CD in this region are in LD with the previously associated risk alleles and can be found on several haplotype backgrounds. People tend to expect the same marker risk alleles when analyzing the same disease in multiple studies. This highlights the difficulties in studies from Abbreviations: CD, celiac disease; CTLA4, cytotoxic T-lymphocyte-associated protein-4; CVID, common variable immunodeficiency; ICOS, inducible co-stimulator; IgAD, IgA deficiency. The frequency of the associated allele in cases and controls is shown, as well as its P-value (if P-value less than 0.05) and odds ratio (OR) and 95% confidence interval (CI).
CTLA4-ICOS locus in celiac disease and IgAD K Haimila et al Table 5 Systematic haplotype comparison of the genetic association and gene expression results of the current study with earlier publications CTLA4-ICOS locus in celiac disease and IgAD K Haimila et al different populations. Failure to replicate previous results or a finding of opposite alleles to previous studies may be due not to disease heterogenity, but rather to the same un-genotyped causative variant existing on several different haplotype backgrounds. Such findings call for more detailed analysis of a locus, including denser genotyping of variants, or even whole-locus sequencing. Polymorphisms within CTLA4-ICOS were analyzed against mRNA expression of CTLA4 and ICOS. In accordance with a previous study, 26 our study demonstrates that a number of the alleles carried in the shared CTLA4-ICOSe1 IgAD and CD risk haplotype associate with higher CTLA4 mRNA expression and lower ICOS mRNA expression, as well as with a higher CTLA4/ ICOS ratio (Table 5d ). Haplotypes k, u and v within the ICOSe2-5 haploblock also demonstrate this same effect on gene expression. The SNPs that associate with CD differ between the Italian (rs11571311*T showing the strongest association) and the Finnish (rs10932037*T) case-control materials, as well as being located in different haplotype blocks. Despite this, both variants were associated with lower ICOS expression levels in stimulated cells. This finding supports the hypothesis that there may be several CD risk haplotypes within the CTLA4-ICOS region with similar biological effects. The allele that is associated with CD risk in the Finnish casecontrol material (rs10932037*T) is also associated with higher expression levels of CTLA4 compared with ICOS in stimulated cells. The rs10932029*T allele, conferring CD risk in Finnish and Hungarian families, appeared to produce a similar expression pattern.
The gene expression results are somewhat in line with two earlier studies examining the functional effect of CTLA4 SNPs. Howard et al.
39 demonstrated higher CTLA4 promoter activity for the rs16840252*Crs5742909*C haplotype. This haplotype occurs frequently within CTLA4-ICOSe1 haplotype group 2, (Table 5a) , although it is also carried by other risk haplotypes (in haplotype groups 1, 2 and 5). In addition, Ueda et al. 40 found higher expression of soluble CTLA4 compared with membrane-bound CTLA4 in carriers of rs3087243*A. The same effect was observed with the Finnish CD risk rs10932037*T allele, although this allele is located in the ICOSe2-5 haploblock.
This study is the first to report association of IgAD with the CTLA4-ICOS locus, and also the first to report shared non-HLA risk variants among IgAD, CVID and CD. Unlike earlier studies, it examined additional tagging SNPs in the intergenic region of CTLA4-ICOS, but it is still difficult to conclude whether the causal variant in CD is in CTLA4 or ICOS, or if a combination of variants within both genes leads to association of the CTLA4-ICOS region with CD. The involvement of both genes would explain the conflicting association and linkage reports from different populations. In summary, several haplotypes in the CTLA4-ICOS locus affect the risk of CD, CVID and IgAD. This may be due to lower expression levels of ICOS and/or comparatively higher levels of CTLA4 or soluble CTLA4.
Materials and methods

Subjects
The study included cohorts of 231 Swedish IgAD individuals and 87 CVID patients, as well as 267 matched controls. The diagnosis of patients with IgAD and CVID was established in accordance with accepted recommendations (European Society for Immunodeficiencies criteria, www.esid.org), on the basis of measurements of Ig levels in multiple independent blood samples. Serum immunoglobulins were measured by routine nephelometry; 41 IgA levels lower than 0.07 mg l À1 were regarded as deficiency. Also included in the study were 44 Finnish IgAD patients, whose deficiency was identified when they served as blood donors. Selective IgAD has been defined by IgA levels lower than 0.05 mg l
À1
. In total, 178 healthy individuals representing the Finnish population were selected as controls.
A total of 385 Hungarian and 278 Finnish celiac families, including 657 and 619 patients, respectively, were entered into the study. The Hungarian family material was collected at the Heim Pal Children's Hospital, Budapest, and at the Department of Paediatrics, University of Debrecen. The Finnish family material was collected at the Tampere University Hospital in collaboration with the Finnish Celiac Society. Diagnosis was based on a small bowel biopsy and/or celiac autoantibody positivity as EmA is known to be highly specific for CD. 42, 43 A subset of 106 Finnish families constitutes an overlap from our earlier study 17 in which 3 of the 18 markers genotyped in this study were the same.
The Italian case-control material consisted of 135 independent single cases and of 184 geographically matched controls. Untreated celiac patients were diagnosed at the 'Burlo Garofolo' Children's Hospital, Trieste, in accordance with European Society of Paediatric Gastroenterology and Nutrition criteria 44 and intestinal biopsies were analyzed using the classification of Oberhuber et al. 45 The patients' serum samples tested positive for both anti-transglutaminase and anti-endomysium antibodies.
Total IgA levels were measured from 89 Finnish controls. Plasma was separated from buffy coat blood of 40 anonymous donors to the Finnish Red Cross Blood Service, Helsinki, Finland, and serum was collected from 49 non-celiac dyspeptic controls (which were negative for both anti-transglutaminase and anti-endomysium antibodies) at the Tampere University Hospital. Samples were stored at À70 1C prior to use. Figure 2 Meta-analysis of association in the combined case-control material. The size of the squares indicates the size of each study population, gray lines refer to 95% confidence interval (CI) of oddsratios (ORs) and x axis refers to OR. The most significant association (P ¼ 0.0005) was found with the intergenic marker rs2882974.
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The ethical committees of the Huddinge University Hospital, Tampere University Hospital, Heim Pal Children's Hospital, University of Debrecen and 'Burlo Garofolo' Children's Hospital approved the study.
Genotyping
All Italian and Swedish cases and controls, as well as Finnish IgAD cases were genotyped for SNPs covering the CTLA4 and ICOS genes as well as the region between the genes; the set of 18 markers included rs231770, rs16840252, rs5742909, rsS231775, rs3087243, rs960792, rs231755, rs2882974, rs10497873, rs11571311, rs3116505, rs10932029, rs4675374, rs4355090, rs4521021, ICOSivs4 þ 1070G/T, rs10172036 and rs10932037. Sixteen partially overlapping haplotype-tagging markers rs16840252, rs231775, rs3087243, rs11571300, rs960792, rs231755, rs2882974, rs10497873, rs11571311, rs3116505, rs11883722, rs10932029, rs4675374, ICOSivs4 þ 1070G/T, rs10172036 and rs10932037 were selected for fine-scale mapping of the CD families and the Finnish and Hungarian CD case-control materials. Rs10172036 and rs10932037 were not genotyped in the CD families; rs10497873 was not genotyped in the case-control materials. All markers were genotyped using the Sequenom MassARRAY system (Sequenom Inc., San Diego, CA, USA), based on matrix-assisted laser desorption/ionization-time of flight technology and primer extension chemistry, either at the Finnish Genome Center, Helsinki, or at the MAF core facility in Karolinska Institute, Stockholm.
HLA typing
Swedish IgAD samples were genotyped at the HLA B, DR and DQ loci using PCR-SSP. 46 The kits used in this study included the HLA-B low resolution (L21, M26, J82, N80, N02, R56, X13 and X82), the HLA-, DQ-, DR SSP Combi Tray (K88, R60, V95, M01 and M84) and the HLA DQB1*06 high resolution (L 46) from Olerup SSP AB, Saltsjöbaden, Sweden.
The Swedish controls and the Finnish controls for IgA levels were genotyped for the SNP rs2187668 previously reported to tag the HLA-DRB1*03-DQA1*05-DQB1*02 haplotype. 37, 47 Genotyping was performed using the On Demand assay by Applied Biosystems, assay number C_58662585_10 (Applied Biosystems, Foster City, CA, USA). Samples were genotyped using the standard protocol provided by Applied Biosystems. PCR assays and allelic discrimination were run on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). In total, 40% of the Swedish IgAD individuals previously HLA typed with traditional methods were genotyped again, using rs2187668, to validate the tagging SNP typing method; all the HLA typing results were concordant.
IgA levels
Total IgA was measured in plasma or serum samples from controls using the Human IgA Quantitation kit (Bethyl Laboratories, Montgomery, AL, USA) according to the manufacturer's instructions.
Gene expression analysis
We further studied the previously published qPCR expression data on ICOS and full-length and soluble CTLA4 (flCTLA4 and sCTLA4, respectively) isoforms in unstimulated (0 h) and stimulated (1, 3 and 6 h) CD4 þ T cells of 17 healthy individuals. 26 The cells were stimulated with anti-CD3 antibody and CD80-mulg fusion protein. The donor samples were genotyped for 10 additional SNPs and the expression level differences were compared between the genotype groups by MannWhitney test (two groups), or Kruskall-Wallis statistics (all three genotype groups were present in sufficient numbers). Absolute expression levels were studied, as well as relative levels of stimulated cells standardized for the 0 h sample in each donor. The ratios of these three transcript levels were also compared between the genotypes.
Statistical analysis
The distributions of all genotypes used in the analyses conformed to the Hardy-Weinberg equilibrium (HWE). Genotyping results and information on pedigree structure and affection status were imported into a BC|GENE LIMS database (Biocomputing Platforms, Espoo, Finland). Deviations from Mendelian inheritance in the family materials were determined with PEDCHECK 1.1. 48 and marker genotypes were discarded in all families where Mendelian inheritance errors were detected. MERLIN 1.0.1 49 was used to perform nonparametric linkage analysis in the Finnish and Hungarian celiac pedigrees. The -pairs and -exp functions were used. Haploview 4.0 50 was used to study LD patterns, estimate haplotypes and perform association analysis. ORs were calculated and two-sided P-values were reported. Genehunter (version 2.1_r5 beta) 51 was used to perform TDTs in the family materials. For TDT, only the index patient or the first diagnosed sibling was selected for the analysis if there was more than one affected individual in a pedigree. Power calculations were performed through the online Genetic Power Calculator. 52 The Cochran-Mantel-Haenszel function in PLINK (available from http://pngu.mgh.harvard.edu/ purcell/plink/) was used to perform a meta-analysis of all combined case-control data sets. Forest plots were produced with the 'forestplot' function in rmeta 2.14 on the R platform available from http://cran.rproject.org/ web/packages/rmeta/index.html. The Breslow-Day test for heterogeneity of ORs was not significant (data not shown), suggesting that the Cochran-Mantel-Haenszel test is appropriate. Rs10172036 was not included in the meta-analysis due to significant HWE deviation in the combined dataset (data not shown).
